Mark Lennihan/AP WASHINGTON -- Sprint (S) has unveiled a plan that gives subscribers access to unlimited data for $60 a month, the industry's cheapest unlimited data offering as the carrier attempts to reverse the decline in its subscriber base. Wireless carriers have been going after each others' subscribers as they try to increase revenue in a nearly saturated market. Sprint's new offerings are $20 cheaper than T-Mobile's unlimited plan and are available to new and existing customers who bring in their own cellphone or pay full price for a new one. The announcement comes just hours after rival T-Mobile US (TMUS) launched a campaign to lure subscribers away from other carriers. If an existing customer is able to persuade a subscriber of another carrier to switch to T-Mobile, both will get upgraded to an unlimited data plan for free for one year. Earlier this week, Sprint doubled data offerings for customers in family plans, while industry leader Verizon Communications slashed prices for its unlimited talk and text plan. Price cuts are a top priority for Sprint's new chief executive, Marcelo Claure, as he attempts to turn around a company plagued by customer defections due to a network overhaul that has caused gaps in coverage. Sprint shares ended Thursday trading up 1.1 percent to $5.56, while T-Mobile shares slipped 1.8 percent to $29.16 on the New York Stock Exchange.
Top 5 Up And Coming Companies To Own In Right Now: InSite Vision Inc (INSV)
InSite Vision Incorporated (InSite), incorporated in 1986, is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company's current portfolio of products is based on the Company's DuraSite sustained drug delivery technology. Its DuraSite sustained drug delivery technology is a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a drug as a solution, gel or suspension and can be customized for delivering a wide variety of drug candidates. The Company is focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology. It may also utilize its DuraSite technology platform for the formulation of new ocular product candidates using either non drugs or compounds developed by others for non-ophthalmic indications.
AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin developed as a spectrum ocular antibiotic and approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Azithromycin has a spectrum of antibiotic activity and is used to treat respiratory and other infections in its oral and parenteral forms.
Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye). Besivance is the fluoroquinolone specifically developed for ophthalmic use. AzaSite Plus (ISV-502) is a fixed combination of azithromycin and dexamethasone in DuraSite for the treatment of ocular inflammation and infection (blepharitis and/or blepharoconjunctivitis).
DexaSite (ISV-305) is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. DexaSite is included in the Phase 3 clinical trial SPA for ! AzaSite Plus. The Company developed a topical formulation of the corticosteroid dexamethasone to treat eye inflammation caused by infections, injury, surgery or other conditions.
BromSite (ISV-303) is a DuraSite formulation of bromfenac in development for the treatment of post-operative inflammation and eye pain. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease.
The Company competes with Alcon Laboratories, Inc., Allergan, Inc., Bausch & Lomb, Novartis Ophthalmics, Johnson & Johnson, Merck & Co. and Pfizer.
Advisors' Opinion:- [By CRWE]
Today, INSV has shed (-2.74%) down -0.009 at $.320 with 15,483 shares in play thus far (ref. google finance Delayed: 10:59AM EDT June 28, 2013), but don�� let this get you down.
InSite Vision Incorporated previously reported the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra�� from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite�� DuraSite庐 topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.
5 Best Cheapest Stocks To Buy Right Now: Ellington Financial LLC (EFC)
Ellington Financial LLC (EFC) is a specialty finance company, which specializes in acquiring and managing mortgage-related assets. As of December 31, 2011, its targeted assets included residential mortgage-backed securities (RMBS), backed by prime jumbo, Alternative A-paper (Alt-A), manufactured housing and subprime residential mortgage loans (non-Agency RMBS); RMBS for which the principal and interest payments are guaranteed by a United States Government agency or a United States Government-sponsored entity (Agency RMBS); mortgage-related derivatives; commercial mortgage-backed securities (CMBS), commercial mortgage loans and other commercial real estate debt, and corporate debt and equity securities and derivatives. It also acquires and manages other types of mortgage-related assets and financial assets, such as residential whole mortgage loans, asset-backed securities (ABS), backed by consumer and commercial assets, non-mortgage-related derivatives and real property.
Non-Agency RMBS
The Company acquires non-Agency RMBS backed by prime jumbo, Alt-A, manufactured housing and subprime residential mortgage loans. Its non-Agency RMBS holdings include investment-grade and non-investment grade classes. Non-Agency RMBS are debt obligations issued by private originators of or investors in residential mortgage loans. Non-Agency RMBS are issued as CMOs and are backed by pools of whole mortgage loans or by mortgage pass-through certificates. Non-Agency RMBS are securitized in senior/subordinated structures, or in excess spread/over-collateralization structures. In senior/subordinated structures, the subordinated tranches absorb all losses on the underlying mortgage loans before any losses are borne by the senior tranches.
Agency RMBS
The Company�� assets in this asset class consist of whole pool pass-through certificates, the principal and interest of which are guaranteed by Federal National Mortgage Association (Fannie Mae), Federal Home Loan Mortgage Cor! poration (Freddie Mac), or Government National Mortgage Association (Ginnie Mae), and which are backed by adjustable rate mortgages (ARMs), hybrid ARMs or fixed-rate mortgages. Mortgage pass-through certificates are securities representing undivided interests in pools of mortgage loans secured by real property where payments of both interest and principal, plus pre-paid principal, on the securities are made monthly to holders of the security, in effect passing through monthly payments made by the individual borrowers on the mortgage loans that underlie the securities, net of fees paid to the issuer/guarantor and servicers of the securities. Whole pool pass-through certificates are mortgage pass-through certificates that represent the entire ownership of a pool of mortgage loans.
In addition to investing in specific pools of Agency RMBS, the Company utilizes forward-settling purchases and sales of Agency RMBS where the underlying pools of mortgage loans are to be announced mortgage-backed securities (MBS) (TBAs). Pursuant to these TBA transactions, it agrees to purchase or sell, for future delivery, Agency RMBS with certain principal and interest terms and certain types of underlying collateral. It uses TBAs for hedging purposes. It engages in TBA transactions for purposes of managing certain risks associated with its long Agency RMBS and its non-Agency RMBS.
Mortgage-Related Derivatives
The Company takes long and short positions in various mortgage-related derivative instruments, including credit default swaps. A credit default swap is a credit derivative contract in which one party (the protection buyer) pays an ongoing periodic premium (and often an upfront payment as well) to another party (the protection seller) in return for compensation for default (or similar credit event) by a reference entity. In this case, the reference entity can be an individual MBS or an index of several MBS, such as an ABX Index, PrimeX or a CMBX Index.
CMBS
CMBS ar! e mortgage-backed securities collateralized by loans on commercial properties. CMBS issued are fixed rate securities backed by fixed rate loans made to multiple borrowers on a range of property types, though single-borrower CMBS and floating-rate CMBS have also been issued. Commercial mortgage loans are loans secured by liens on commercial properties, including retail, office, industrial, hotel and multifamily properties. Commercial real estate loans may also be structured into more complicated senior/subordinate structures, including those providing for multiple B-Note or multiple mezzanine loan senior/subordinate components.Corporate Debt and Equity Securities and Derivatives
For hedging purposes, the Company takes short positions in corporate debt and equity (including indices on corporate debt and equity) by entering into derivative contracts, such as credit default swaps, total return swaps and options. These hedges reference corporations (such as financial institutions that have substantial mortgage-related exposure) or indices whose performance has a degree of correlation with the performance of its portfolio. Given this correlation, a short position with respect to such corporations or indices provides a hedge to its portfolio of MBS as a whole.
Other Assets
The Company from time to time acquires other mortgage-related and financial assets, which include residential whole mortgage loans, ABS backed by consumer and commercial assets and real property. It also acquires real property interests, such as single family and multifamily residential properties.
Advisors' Opinion:- [By Luke Jacobi]
Ellington Financial LLC (NYSE: EFC) was down, falling 4.4 percent to $23.53 after the company priced 8 million shares at $23.92 per share.
CommoditiesAlthough equities have been flat, the same cannot be said for the commodity market. Crude futures shot higher Wednesday, following yesterday’s sharp sell off. At last check, WTI futures were up 2.7 percent to $95.37 and Brent futures gained 2.1 percent to $102.45.
5 Best Cheapest Stocks To Buy Right Now: Thoratec Corporation(THOR)
Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The company?s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge, and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising hom e discharge, and post-cardiotomy myocardial recovery. The company also provides CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure. In addition, it offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. The company sells its products through direct sales force in the United States, as well as through a network of distributors internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.
Advisors' Opinion:- [By Todd Campbell]
Competing for heart pump market share
Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR ) and Heartware (NASDAQ: HTWR ) target the intermediate- and long-term-use market instead.
5 Best Cheapest Stocks To Buy Right Now: IGI Laboratories Inc. (IG)
IGI Laboratories, Inc. engages in developing, manufacturing, filling, and packaging topical semi-solid and liquid products for cosmetic, cosmeceutical, and pharmaceutical customers in the United States. The company�s products are used for various skin conditions, including the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. It offers contract formulation and contract manufacturing services to a range of topical formulations, including creams, ointments, lotions, gels, and topical liquids. The company is also developing a portfolio of prescription generic formulations in topical dosage forms. IGI Laboratories, Inc., through its license agreement with Novavax, Inc., utilizes the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.
Advisors' Opinion:- [By Holly LaFon]
The Barclays Aggregate Index rose by 0.57% in 3Q13, having stood at a loss of -0.36% the day before the FOMC's declaration to not slow QE. Despite the bounce, the Index remains in negative territory YTD and for the trailing 12-months at -1.77% and -1.68%, respectively. In stark contrast to 2Q13, Investment Grade (IG) corporate spreads tightened 10bps during 3Q13, producing a positive nominal return of 0.82% and an excess return of 0.92%. The respective YTD total returns in IG remain a disappointing -2.62%, but excess returns are still positive at 0.61% YTD. The 1-Yr results for IG Credit now fall to a nominal -1.58%, but 1.79% in excess of Treasuries.
No comments:
Post a Comment